Patents Assigned to JCR Pharmaceuticals Co., Ltd.
-
Patent number: 8569232Abstract: Disclosed are method for treating diabetes, a protein for treatment of diabetes, and pharmaceutical composition comprising the same. The protein is human mature chemerin, which can be used to treat diabetes, in particular type 2 diabetes, inter alia to treat diabetes in a patient who is concurrently administered with insulin.Type: GrantFiled: October 17, 2008Date of Patent: October 29, 2013Assignees: Kobe University, JCR Pharmaceuticals Co., Ltd.Inventors: Yutaka Takahashi, Kazuo Chihara
-
Publication number: 20130244231Abstract: Disclosed are a novel expression vector for efficient expression of recombinant proteins in mammalian cells, a mammalian cell transformed with the vector, and a method for production of the mammalian cell. The expression vector includes a gene expression regulatory site, and a gene encoding the protein downstream thereof, and an internal ribosome entry site further downstream thereof, and a gene encoding a glutamine synthetase further downstream thereof.Type: ApplicationFiled: November 8, 2011Publication date: September 19, 2013Applicant: JCR PHARMACEUTICALS CO., LTD.Inventor: Kenichi Takahashi
-
Patent number: 8522603Abstract: Disclosed is an improved post-column fluorimetric determination-boric acid complex anion exchange method which allows analysis of mannose-6-phosphate. The disclosed method is a method for separation analysis of reducing sugars using column chromatography, comprising loading a sample onto an anion exchange column, washing the column by allowing to flow a sufficient volume of a first mobile phase consisting of an aqueous solution of a predetermined concentration of boric acid containing a predetermined concentration of a water-soluble inorganic salt through the column, supplying a second mobile phase with an elevated concentration of the salt to elute the reducing sugars, adding to the eluate a basic amino acid, heating, and continuously measuring and recording the intensity of fluorescent light emitted under irradiation with excitation light.Type: GrantFiled: March 12, 2010Date of Patent: September 3, 2013Assignee: JCR Pharmaceuticals Co., Ltd.Inventor: Tetsuo Yokoyama
-
Publication number: 20130224797Abstract: Disclosed is a method for producing a glycoprotein using mammalian cells, wherein all or part of the non-reducing ends of N-glycoside binding sugar chains are mannose residues. The method is a method for producing glycoproteins using transformant mammalian cells which are prepared by introducing thereinto a ?-N-acetylglucosaminidase gene and inducing its expression.Type: ApplicationFiled: October 13, 2011Publication date: August 29, 2013Applicant: JCR PHARMACEUTICALS CO., LTD.Inventor: Kenichi Takahashi
-
Patent number: 8465733Abstract: Disclosed are a method for producing a frozen pharmaceutical composition prepared from cultured human mesenchymal stem cells and a pharmaceutical composition containing human mesenchymal stem cells. This method is a method for producing a frozen pharmaceutical composition containing human mesenchymal stem cells, which comprises the following steps in this order: (a) adding trypsin to human mesenchymal stem cells in a culture vessel to detach the cells from the surface of the culture vessel; (b) adding a bicarbonate Ringer's solution containing human serum albumin to the detached cells to terminate the reaction with trypsin, and washing the cells with the bicarbonate Ringer's solution containing human serum albumin; (c) suspending the cells in a bicarbonate Ringer's solution containing human serum albumin and dimethyl sulfoxide; (d) putting the resulting suspension in a container which allows freezing of what is contained therein, and sealing the container; and (e) freezing the suspension put in the container.Type: GrantFiled: October 27, 2008Date of Patent: June 18, 2013Assignee: JCR Pharmaceuticals Co., Ltd.Inventors: Hiroyuki Shirono, Youngjin Byun, Shoichiro Kamei, Kiwamu Imagawa
-
Publication number: 20130095570Abstract: Disclosed is a method separation analysis of reducing sugars with enhanced sensitivity and an analytical apparatus therefore employing the post-column fluorescence detection/boric acid complex anion exchange method. The method disclosed is a method for analysis of reducing sugars using the post-column fluorescence detection/boric acid complex anion exchange method, and characterized in that a back-pressure generator is installed in the flow path between the heater, which is for causing a reaction by heating a sample separated by column chromatography with a basic amino acid, and a fluorometric detector.Type: ApplicationFiled: April 25, 2011Publication date: April 18, 2013Applicant: JCR PHARMACEUTICALS CO., LTD.Inventor: Tetsuo Yokoyama
-
Publication number: 20130023726Abstract: Means for improving the success rate of pregnancy on the basis of blastocyst transfer is disclosed. The means comprises an agent for promoting pregnancy in blastocyst transfer comprising the supernatant of the culture which is obtained by culturing a human embryo in a medium until the embryo develops into a blastocyst. Also disclosed are a method for production of the agent, as well as a method for promoting pregnancy comprising; culturing a human embryo in a medium until the human embryo develops into a blastocyst, injecting a composition comprising the supernatant of the culture into the uterine cavity of a patient who is to undergo blastocyst transfer, and then transferring the blastocyst to the recipient.Type: ApplicationFiled: September 25, 2012Publication date: January 24, 2013Applicant: JCR PHARMACEUTICALS CO., LTD.Inventor: JCR PHARMACEUTICALS CO., LTD.
-
Patent number: 8348902Abstract: An injection device adapted to the luer lock system and a syringe holder for making it is disclosed. The syringe holder for holding an inserted syringe, with a cap attached to the male luer at the tip, comprises a cylindrical barrel portion having an open distal end and an open proximal end, and a finger rest around the outer surface of the barrel portion at a position relatively closer to the proximal end, wherein a stopper means is provided at the inner surface of the barrel portion at the distal end thereof, the stopper means being designed to abut on the outer edge of the distal end of the syringe, and wherein a female-threaded sleeve extends forwardly from the distal end of the barrel portion, which is designed to surround the tip of the syringe and the cap, and wherein a proximal end cap is provided, at the proximal end of the barrel portion, which is designed to abut on the outer edge of the proximal end of the syringe, and has a bore to pass the piston rod through.Type: GrantFiled: October 26, 2006Date of Patent: January 8, 2013Assignee: JCR Pharmaceuticals Co., Ltd.Inventors: Kouichi Sugita, Hiroshi Matsumoto
-
Patent number: 8299018Abstract: Disclosed are a fusion protein comprising enzyme N-acetylgalactosamine-6-sulfate sulfatase and a short peptide consisting of 4-15 acidic amino acids attached to the enzyme on its N-terminal side, a pharmaceutical composition containing the fusion protein, and a method for treatment of type A Morquio disease using the fusion protein. Compared with the native enzyme protein, the fusion protein exhibits higher transferability to bone tissues and improved, higher stability in the blood.Type: GrantFiled: December 12, 2008Date of Patent: October 30, 2012Assignees: Saint Louis University, Kanazawa University, JCR Pharmaceuticals Co., Ltd.Inventors: Shunji Tomatsu, Ken'ichi Miyamoto, Masamichi Yamada, Yasuhiro Tosaka, Mana Yamada
-
Publication number: 20120220553Abstract: The objective is to find compounds which have an activity to improve the success rate of pregnancy and implantation in blastocyst transfer in mammals, to provide a method of producing and using the compounds, and to provide a pregnancy-promoting agent. Disclosed is a pregnancy-promoting agent containing one or more lysophosphatidic acids selected from the group consisting of LPA-C16:0, LPA-C16:1, LPA-C18:0, LPA-C18:1 and LPA-C18:2.Type: ApplicationFiled: August 25, 2010Publication date: August 30, 2012Applicant: JCR Pharmaceuticals Co., Ltd.Inventors: Masahide Shiotani, Sakae Goto, Mitsuo Shimizu
-
Patent number: 8241647Abstract: The present invention provides an amphiphilic molecule having a plurality of zwitterionic functional groups in its hydrophilic moiety and a molecular assembly comprising the amphiphilic molecule as a constituent lipid. The molecular assembly of the present invention forms a stable vesicular structure under a physiological pH environment to carry a substance of interest in the vesicular structure, and can release the substance of interest to the outside of the vesicular structure when it is deformed under an acidic pH environment. The molecular assembly of the present invention can be used as a carrier for a drug, a probe, a nucleic acid, a protein or the like.Type: GrantFiled: May 16, 2008Date of Patent: August 14, 2012Assignees: Waseda University, JCR Pharmaceuticals Co. Ltd.Inventors: Shinji Takeoka, Yosuke Obata, Shoji Tajima, Manabu Ito, Atsushi Mizuno, Natsuko Nishiyama, Yoshito Takeuchi
-
Publication number: 20110274663Abstract: Disclosed are a method for producing a frozen pharmaceutical composition prepared from cultured human mesenchymal stem cells and a pharmaceutical composition containing human mesenchymal stem cells. This method is a method for producing a frozen pharmaceutical composition containing human mesenchymal stem cells, which comprises the following steps in this order: (a) adding trypsin to human mesenchymal stem cells in a culture vessel to detach the cells from the surface of the culture vessel; (b) adding a bicarbonate Ringer's solution containing human serum albumin to the detached cells to terminate the reaction with trypsin, and washing the cells with the bicarbonate Ringer's solution containing human serum albumin; (c) suspending the cells in a bicarbonate Ringer's solution containing human serum albumin and dimethyl sulfoxide; (d) putting the resulting suspension in a container which allows freezing of what is contained therein, and sealing the container; and (e) freezing the suspension put in the container.Type: ApplicationFiled: October 27, 2008Publication date: November 10, 2011Applicant: JCR Pharmaceuticals Co., Ltd.Inventors: Hiroyuki Shirono, Youngjin Byun, Shoichiro Kamei, Kiwamu Imagawa
-
Patent number: 7939296Abstract: Disclosed is a method for production of recombinant human FSH in high yield and a high purity. The method comprises the steps of: (a) culturing recombinant human FSH-producing mammalian cells in a serum-free medium, (b) collecting culture supernatant, (c) subjecting the culture supernatant to cation-exchange column chromatography, (d) dye affinity column chromatography, (e) hydrophobic column chromatography, and (f) gel filtration column chromatography to collect recombinant human FSH-active fractions, in the order.Type: GrantFiled: May 15, 2009Date of Patent: May 10, 2011Assignee: JCR Pharmaceuticals Co., Ltd.Inventors: Atsushi Sugimura, Katsuya Daimon, Kazutoshi Mihara, Yae Ito
-
Publication number: 20110105734Abstract: Disclosed is a method for production of human erythropoietin. By the method, the cells are cultured in a serum-free medium with repetitive medium exchanges, in which medium exchange is carried out either by collecting 80 to 95% of the culture when viable cell density has reached at 2×106˜4×106 cells/mL, or by adjusting the amount of the exchanged medium so that the initial density of the viable cells may be 1.5×105˜2.5×105 cells/mL.Type: ApplicationFiled: December 19, 2006Publication date: May 5, 2011Applicant: JCR Pharmaceuticals Co., Ltd.Inventors: Atsuko Kawasaki, Keisuke Mukai, Sei Kirihara
-
Publication number: 20110046055Abstract: Disclosed are method for treating diabetes, a protein for treatment of diabetes, and pharmaceutical composition comprising the same. The protein is human mature chemerin, which can be used to treat diabetes, in particular type 2 diabetes, inter alia to treat diabetes in a patient who is concurrently administered with insulin.Type: ApplicationFiled: October 17, 2008Publication date: February 24, 2011Applicants: KOBE UNIVERSITY, JCR PHARMACEUTICALS CO., LTD.Inventors: Yutaka Takahashi, Kazuo Chihara
-
Publication number: 20110027859Abstract: Disclosed is an efficient method for production of aminopeptidase. The method comprises either transforming host bacteria with an aminopeptidase gene and with a neutral protease gene, or transforming some part of host bacteria with an aminopeptidase gene while transforming the other part of the host bacteria with a neutral protease gene, culturing in a medium the hose bacteria transformed with the aminopeptidase gene and with the neutral protease gene, or culturing a mixture of the host bacteria transformed with the aminopeptidase gene and the host bacteria transformed with the neutral protease gene, to let both the aminopeptidase and the neutral protease be expressed, and collecting the aminopeptidase thus produced from the culture mixture.Type: ApplicationFiled: October 25, 2008Publication date: February 3, 2011Applicant: JCR PHARMACEUTICALS CO., LTDInventors: Hiroyuki Sonoda, Katsuya Daimon
-
Patent number: 7863238Abstract: Disclosed are a fusion protein comprising enzyme N-acetylgalactosamine-6-sulfate sulfatase and a short peptide consisting of 4-15 acidic amino acids attached to the enzyme on its N-terminal side, a pharmaceutical composition containing the fusion protein, and a method for treatment of type A Morquio disease using the fusion protein. Compared with the native enzyme protein, the fusion protein exhibits higher transferability to bone tissues and improved, higher stability in the blood.Type: GrantFiled: June 10, 2004Date of Patent: January 4, 2011Assignees: Saint Louis University, Kanazawa University, JCR Pharmaceuticals Co., Ltd.Inventors: Shunji Tomatsu, Ken'ichi Miyamoto, Masamichi Yamada, Yasuhiro Tosaka, Mana Yamada
-
Publication number: 20100229634Abstract: Disclosed is an improved post-column fluorimetric determination-boric acid complex anion exchange method which allows analysis of mannose-6-phosphate. The disclosed method is a method for separation analysis of reducing sugars using column chromatography, comprising loading a sample onto an anion exchange column, washing the column by allowing to flow a sufficient volume of a first mobile phase consisting of an aqueous solution of a predetermined concentration of boric acid containing a predetermined concentration of a water-soluble inorganic salt through the column, supplying a second mobile phase with an elevated concentration of the salt to elute the reducing sugars, adding to the eluate a basic amino acid, heating, and continuously measuring and recording the intensity of fluorescent light emitted under irradiation with excitation light.Type: ApplicationFiled: March 12, 2010Publication date: September 16, 2010Applicant: JCR PHARMACEUTICALS CO., LTD.Inventor: Tetsuo YOKOYAMA
-
Publication number: 20100209458Abstract: The present invention provides an amphiphilic molecule having a plurality of zwitterionic functional groups in its hydrophilic moiety and a molecular assembly comprising the amphiphilic molecule as a constituent lipid. According to a preferred embodiment of the present invention, the molecular assembly of the present invention forms a stable vesicular structure under a physiological pH environment to carry a substance of interest in the vesicular structure, and can release the substance of interest to the outside of the vesicular structure when it is deformed under an acidic pH environment. The molecular assembly of the present invention can be used as a carrier for a drug, a probe, a nucleic acid, a protein or the like.Type: ApplicationFiled: May 16, 2008Publication date: August 19, 2010Applicants: Waseda University, JCR Pharmaceuticals Co., Ltd.Inventors: Shinji Takeoka, Yosuke Obata, Shoji Tajima, Manabu Ito, Atsushi Mizuno, Natsuko Nishiyama, Yoshito Takeuchi
-
Publication number: 20090297592Abstract: It is an object of the present invention to provide an enzyme preparation which is excellent in stability in blood (blood residence) and in transfer to a target organ (targeting property), and can be used effectively in enzyme replacement therapy or the like. This problem is solved by a lipid vesicle composition wherein vesicles composed of a lipid bilayer membrane are encapsulating an enzyme, the composition being capable of retaining stably the activity of the enzyme even outside the stable pH range of the enzyme.Type: ApplicationFiled: May 11, 2006Publication date: December 3, 2009Applicants: JCR Pharmaceuticals Co., Ltd., Tokyo Metropolitan Organization for Medical ResearchInventors: Hitoshi Sakuraba, Youichi Tajima, Ikuo Kawashima, Mai Ito, Shinji Takeoka, Katsuji Ohta, Manabu Ito, Atsushi Mizuno